BlackRock Investment Management’s Ocular Therapeutix OCUL Stock Holding History

BlackRock Investment Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$594K	Buy	70,932 +204	+0.3%	+$1.58K	﹤0.01%	2985
2016 Q3	$486K	Buy	70,728 +9,255	+15%	+$56.4K	﹤0.01%	3061
2016 Q2	$304K	Buy	61,473 +7,660	+14%	+$75.9K	﹤0.01%	3222
2016 Q1	$520K	Buy	53,813 +1,126	+2%	+$8.53K	﹤0.01%	2888
2015 Q4	$494K	Buy	52,687 +428	+0.8%	+$4.62K	﹤0.01%	3013
2015 Q3	$735K	Buy	52,259 +6,132	+13%	+$123K	﹤0.01%	2829
2015 Q2	$970K	Buy	46,127 +28,945	+168%	+$717K	﹤0.01%	2782
2015 Q1	$721K	Buy	17,182 +761	+5%	+$25K	﹤0.01%	2754
2014 Q4	$386K	Buy	16,421 +907	+6%	+$15.3K	﹤0.01%	3112
2014 Q3	$232K	Buy	+15,514	New	+$229K	﹤0.01%	3226

Other funds holding OCUL

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

BlackRock Investment Management's OCUL Position: Q4 2016 in Review

BlackRock Investment Management increased its Ocular Therapeutix (OCUL) stake by 0.29% in Q4 2016, buying an estimated $1.58K and bringing the position to 70,932 shares worth $594K. The position accounts for ﹤0.01% of the portfolio, ranked #2985.

BlackRock Investment Management first reported a position in OCUL in Q3 2014 and has held it in 10 quarters since. The position peaked at $970K in Q2 2015. 76 funds tracked by Wall St. Rank hold OCUL as of Q4 2016.

BlackRock Investment Management held 70,932 shares of Ocular Therapeutix worth $594K as of Q4 2016.
BlackRock Investment Management bought 204 Ocular Therapeutix shares in Q4 2016, an estimated $1.58K.
Ocular Therapeutix made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2985 holding.
BlackRock Investment Management first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 10 quarters since.
BlackRock Investment Management's Ocular Therapeutix position peaked at $970K in Q2 2015.
76 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.